Related Experiment Videos

Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The

Andrew P Levy1, Irit Hochberg, Kathleen Jablonski

  • 1Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. alevy@tx.technion.ac.il

Journal of the American College of Cardiology
|December 12, 2002
PubMed

Insights

Haptoglobin phenotype predicts cardiovascular disease (CVD) risk in patients with diabetes mellitus (DM). The haptoglobin 2-2 phenotype significantly increases CVD risk, suggesting its use in risk stratification for diabetic patients.

Area of Science:

  • Genetics and Cardiovascular Medicine
  • Diabetes Mellitus Research

Background:

  • Cardiovascular disease (CVD) is a major complication of type 2 diabetes mellitus (DM).
  • Ethnic and geographic variations in CVD risk in DM patients are not fully explained by conventional risk factors.
  • Haptoglobin gene polymorphism is a known determinant of microvascular complications in DM.

Purpose of the Study:

  • To investigate if haptoglobin phenotype predicts cardiovascular disease (CVD) risk in diabetic mellitus (DM).
  • To extend the known role of haptoglobin in microvascular complications to macrovascular complications in DM.

Main Methods:

  • Case-control study using data from the Strong Heart study.
  • Haptoglobin phenotype determined by polyacrylamide gel electrophoresis in 206 CVD cases and 206 matched controls (ages 45-74).
  • Multivariate analyses controlling for conventional CVD risk factors; median follow-up of six years.

Main Results:

  • Haptoglobin phenotype was a significant, independent predictor of CVD in DM.
  • The haptoglobin 2-2 phenotype was associated with a 5.0-fold increased odds of CVD compared to the haptoglobin 1-1 phenotype (p=0.002).
  • The haptoglobin 2-1 phenotype indicated an intermediate CVD risk.

Conclusions:

  • Haptoglobin phenotype determination may enhance CVD risk stratification algorithms in diabetic patients.
  • Haptoglobin phenotype could aid in evaluating novel therapies for CVD prevention in DM.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...